abstract |
Provided is a method for the treatment and / or prevention of autoinflammatory syndromes, such as juvenile rheumatoid arthritis or rheumatoid arthritis syndrome. An IL-1β binding molecule comprising both a heavy chain (VH) variable domain and a light chain (VL) variable domain, which in turn comprises the hypervariable regions CDR1, CDR2 and CDR3. (VH), wherein the CDR1 comprises the amino acid sequence Val-Tyr-Gly-Met-Asn, and the CDR2 comprises the amino acid sequence Ile-Ile-Trp-Tyr-Asp-Gly-Asp-Asn-Gln-Tyr-Tyr A medicament comprising at least one antigen-binding site such as a domain (VH) consisting of Ala-Asp-Ser-Val-Lys-Gly, and wherein the CDR3 consists of the amino acid sequence Asp-Leu-Arg-Thr-Gly-Pro. [Selection figure] None |